Search Result

Results for "

recruiting

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Ligands for E3 Ligase (851) 5-HT Receptor (7) Acetyl-CoA Carboxylase (1) Adenosine Receptor (4) Adenylate Cyclase (1) Adrenergic Receptor (3) Akt (7) Aminopeptidase (2) Anaplastic lymphoma kinase (ALK) (2) Androgen Receptor (2) Antibiotic (1) Apelin Receptor (APJ) (6) Apoptosis (137) Arrestin (33) Atg8/LC3 (2) ATM/ATR (1) Aurora Kinase (1) Autophagy (111) Bacterial (6) Bcl-2 Family (5) BCL6 (1) Bcr-Abl (2) Biochemical Assay Reagents (4) BMI1 (1) Btk (5) ByeTAC (1) c-Fms (1) c-Met/HGFR (2) c-Myc (3) Calcium Channel (6) Cannabinoid Receptor (3) Carbonic Anhydrase (3) Casein Kinase (1) Caspase (12) Cathepsin (1) CCR (11) CD20 (2) CD3 (7) CD38 (1) CDK (9) CFTR (4) CGRP Receptor (1) Checkpoint Kinase (Chk) (1) Chemerin Receptor (1) Complement System (3) Constitutive Androstane Receptor (1) COX (1) CXCR (24) Cyclic GMP-AMP Synthase (1) Cyclophilin (2) Cytochrome P450 (2) Deubiquitinase (7) DGK (1) DNA Methyltransferase (4) DNA/RNA Synthesis (13) Dopamine Receptor (12) Drug Derivative (4) Drug Isomer (2) Drug Metabolite (1) DUBTACs (2) E1/E2/E3 Enzyme (6) E3 Ligase Ligand-Linker Conjugates (198) EBI2/GPR183 (1) EBV (1) EGFR (7) Endogenous Metabolite (9) Enterovirus (1) Environmental Pollutants (1) Epigenetic Reader Domain (31) ERK (14) Estrogen Receptor/ERR (7) Eukaryotic Initiation Factor (eIF) (1) FGFR (1) FKBP (3) FLT3 (2) Formyl Peptide Receptor (FPR) (1) Free Fatty Acid Receptor (2) FXR (3) G protein-coupled Bile Acid Receptor 1 (2) GCGR (2) GLP Receptor (6) Glutathione Peroxidase (3) GPR35 (1) GPR39 (1) GPR55 (2) GPR65 (2) GPR84 (2) GSK-3 (1) HBV (1) HCV (3) HDAC (5) Hippo (MST) (1) Histamine Receptor (6) Histone Acetyltransferase (5) Histone Demethylase (1) Histone Methyltransferase (14) HIV (7) HSP (1) HSV (2) Huntingtin (1) HuR (1) Hydroxycarboxylic Acid Receptor (HCAR) (1) HyT (1) IAP (6) IFNAR (7) IGF-1R (1) iGluR (2) IKK (3) IKZF Family (5) Indoleamine 2,3-Dioxygenase (IDO) (1) Influenza Virus (1) Insecticide (2) Integrin (6) Interleukin Related (13) IRAK (2) Isotope-Labeled Compounds (5) JAK (4) JNK (2) Keap1-Nrf2 (2) Kinesin (1) Large Tumor Suppressor (LATS) (1) Leukotriene Receptor (1) Ligands for Target Protein for PROTAC (5) LPL Receptor (1) LRRK2 (1) LYTACs (2) mAChR (1) MALT1 (1) MAP3K (1) MAPKAPK2 (MK2) (1) Mas-related G-protein-coupled Receptor (MRGPR) (3) MDM-2/p53 (4) MEK (3) Microtubule/Tubulin (1) Mitochondrial Metabolism (1) Mitophagy (1) Mitosis (1) Mixed Lineage Kinase (1) MMP (2) Molecular Glues (29) mRNA (4) MyD88 (3) Neuropeptide Y Receptor (3) Neurotensin Receptor (2) NF-κB (8) NOD-like Receptor (NLR) (1) Notch (2) Nucleoside Antimetabolite/Analog (1) Opioid Receptor (15) Orphan Nuclear Receptor (3) Oxidative Phosphorylation (1) Oxysterol-binding Protein-related Protein (ORP) (2) P-glycoprotein (2) P2Y Receptor (2) p38 MAPK (6) p62 (1) Parasite (2) PARP (8) PD-1/PD-L1 (5) PDGFR (1) Peptide-Drug Conjugates (PDCs) (1) PERK (5) PGC-1α (1) Phosphatase (3) Phosphodiesterase (PDE) (2) PhosTACs (2) PI3K (5) Pim (1) PINK1/Parkin (2) PKA (1) PKC (1) Polo-like Kinase (PLK) (1) Potassium Channel (1) PPAR (5) Prion Protein (1) Prolyl Endopeptidase (PREP) (1) Prostaglandin Receptor (2) PROTAC Linkers (1) PROTACs (92) Protease Activated Receptor (PAR) (3) Proteasome (1) Proteasome Cap Targeting Chimeras (1) PSMA (1) PTHR (2) Pyroptosis (2) RAD51 (1) Raf (1) Ras (8) Reactive Oxygen Species (ROS) (2) Reference Standards (9) RET (1) REV-ERB (1) RIO Kinase (1) RIP kinase (2) ROR (1) RXFP Receptor (1) SARS-CoV (1) Serotonin Transporter (1) SHP1 (1) Sirtuin (1) SNIPERs (3) Sodium Channel (2) Src (3) STAT (6) STING (4) SWI/SNF Complex (2) Syk (2) Target Protein Ligand-Linker Conjugates (41) Tau Protein (2) TGF-β Receptor (2) Thymidylate Synthase (2) Thyroid Hormone Receptor (1) TNF Receptor (10) Toll-like Receptor (TLR) (5) Transmembrane Glycoprotein (2) Trk Receptor (1) Tyrosinase (1) VD/VDR (1) VEGFR (1) WDR5 (2) Wee1 (5) Wnt (1) YAP (5) β-catenin (1)
By Research Areas:	Cancer (1299) Cardiovascular Disease (28) Endocrinology (12) Infection (32) Inflammation/Immunology (119) Metabolic Disease (36) Neurological Disease (64)
Click Chemistry:	DBCO (1) PROTAC Synthesis (3) Azide (7) Tetrazine (1) Alkynes (7)
Oligonucleotides:	Aptamers (1) Chemokine & Receptors (3) CpG ODNs (1) Phospholipids (1) mRNA (4) Antisense Oligonucleotides (2) Cap Analogs (1) Interleukin & Receptors (1)

1522

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

Targets Recommended: Ligands for E3 Ligase

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-116767

BLT-1 10+ Cited Publications Block lipid transport-1	HCV	Metabolic Disease Inflammation/Immunology
BLT-1, a thiosemicarbazone copper chelator, is a selective scavenger receptor B, type 1 (SR-BI) inhibitor. BLT-1 inhibits the transfer of lipids between high-density lipoproteins (HDL) and cells mediated by SR-BI. BLT-1 is a potent HCV entry inhibitor .

HY-119339

SX-682 5+ Cited Publications	CXCR	Inflammation/Immunology Endocrinology Cancer
SX-682 is an orally bioavailable, potent allosteric inhibitor of CXCR1 and CXCR2. SX-682 can block tumor myeloid-derived suppressor cells (MDSCs) recruitment and enhance T cell activation and antitumor immunity .

HY-141513

NH-3 4 Publications Verification	Thyroid Hormone Receptor	Neurological Disease
NH-3 is an orally active, reversible thyroid hormone receptor (THR) antagonist with an IC₅₀ of 55 nM. NH-3, a derivative of the selective thyromi-metic GC-1, inhibits binding of thyroid hormones to their receptor and that inhibits cofactor recruitment . NH-3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-W077589

Lenalidomide-5-aminomethyl hydrochloride	Ligands for E3 Ligase	Cancer
Lenalidomide-5-aminomethyl hydrochloride is the Lenalidomide-based cereblon (CRBN) ligand used in the recruitment of CRBN protein. Lenalidomide-5-aminomethyl hydrochloride can be connected to the ligand for protein by a linker to form PROTAC

HY-50688

SB-265610 5+ Cited Publications	CXCR	Inflammation/Immunology
SB-265610 is a selective, competitive, nonpeptide and allosteric CXCR2 antagonist. SB-265610 blocks rat cytokine-induced neutrophil chemoattractant-1 (CINC-1)-induced calcium mobilization and neutrophil chemotaxis with IC₅₀s of 3.7 nM and 70 nM, respectively .

HY-23095

Thalidomide-5-OH	Ligands for E3 Ligase Autophagy Apoptosis	Cancer
Thalidomide-5-OH is the Thalidomide-based cereblon ligand used in the recruitment of CRBN protein. Thalidomide-5-OH can be connected to the ligand for protein by a linker to form PROTACs .

HY-120645

BMS-986122 1 Publications Verification	Opioid Receptor	Neurological Disease
BMS-986122 is a selective, potent positive allosteric modulator of the mu-opioid receptor (µ-OR). BMS-986122 shows potentiation of orthosteric agonist-mediated β-arrestin recruitment, adenylyl cyclase inhibition, and G protein activation. BMS-986122 potentiates DAMGO-mediated [ ³⁵S]GTPγS binding in mouse brain membranes .

HY-139539

Thalidomide-5-COOH	Ligands for E3 Ligase Autophagy Apoptosis	Cancer
Thalidomide-5-COOH is the Thalidomide-based cereblon ligand used in the recruitment of CRBN protein. Thalidomide-5-COOH can be connected to the ligand for protein by a linker to form PROTACs .

HY-128121

MLS1547	Dopamine Receptor	Neurological Disease
MLS1547 is a highly efficacious G protein-biased dopamine D2 receptor (D2R) agonist (K_i=1.2 μM). MLS1547 stimulates D2R G protein-mediated signaling (EC₅₀=0.37 μM in a calcium mobilization assay). MLS1547 acts as an antagonist for dopamine (DA)-stimulated β-arrestin recruitment to the D2R (IC₅₀=9.9 μM) .

HY-P1682A

Balixafortide TFA 1 Publications Verification POL6326 TFA	CXCR Arrestin	Cancer
Balixafortide TFA (POL6326 TFA) is a potent, selective, well-tolerated peptidic CXCR4 antagonist with an IC₅₀ < 10 nM. Balixafortide TFA shows 1000-fold selective for CXCR4 than a large panel of receptors including CXCR7. Balixafortide TFA blocks β-arrestin recruitment and calcium flux with IC₅₀s < 10 nM. Balixafortide TFA is also a potent hematopoietic stem and progenitor cell (HSPC) mobilizing agent. Anti-cancer effects .

HY-156828

MMH2	Molecular Glues Epigenetic Reader Domain	Cancer
MMH2 is a novel BRD4 molecular glue degrader that functions by recruiting the CUL4 and DCAF16 ligases to the second bromodomain of BRD4 (BRD4_BD2) .

HY-W072954

Lenalidomide-5-Br	Ligands for E3 Ligase	Cancer
Lenalidomide-5-Br is the Lenalidomide-based cereblon (CRBN) ligand used in the recruitment of CRBN protein. Lenalidomide-5-Br can be connected to the ligand for protein by a linker to form PROTAC .

HY-143345

EN523	Deubiquitinase	Cancer
EN523 is a OTUB1 recruiter. EN523 targets a non-catalytic allosteric cysteine C23 in the K48-ubiquitin-specific deubiquitinase OTUB1 .

HY-128756

SIAIS178	PROTACs Bcr-Abl	Cancer
SIAIS178 is a potent and selective BCR-ABL degrader based on PROTAC technology with an IC₅₀ of 24 nM. SIAIS178 causes effective degradation of BCR-ABL protein by recruiting Von Hippel-Lindau (VHL) E3 ubiquitin ligase. SIAIS178 has anticancer activity .

HY-P1682

Balixafortide 1 Publications Verification POL6326	CXCR Arrestin	Cancer
Balixafortide (POL6326) is a potent, selective, well-tolerated peptidic CXCR4 antagonist with an IC₅₀ < 10 nM. Balixafortide shows 1000-fold selective for CXCR4 than a large panel of receptors including CXCR7. Balixafortide blocks β-arrestin recruitment and calcium flux with IC₅₀s < 10 nM. Balixafortide is also a potent hematopoietic stem and progenitor cell (HSPC) mobilizing agent. Anti-cancer effects .

HY-145696

SJ10542	PROTACs JAK	Inflammation/Immunology Cancer
SJ10542 is a potent and selective JAK2/3 PROTAC degrader. In PDX cells lSJBALL020589, SJ10542 has DC₅₀ values of 14 and 11 nM for JAK2 and JAK3, respectively. SJ10542 exhibits antitumor activity and can be used for the research of hematological malignancies and autoimmune diseases . (Pink: Target protein ligand (HY-47073); Black: Linker (HY-W251248); Blue: E3 ligase ligand (HY-W890189); E3 ligase ligand+Linker (HY-176425))

HY-156827

MMH1	Molecular Glues Epigenetic Reader Domain	Cancer
MMH1 is a novel BRD4 molecular glue degrader that functions by recruiting the CUL4 and DCAF16 ligases to the second bromodomain of BRD4 (BRD4_BD2) .

HY-174140

VU0514009	Chemerin Receptor	Metabolic Disease Inflammation/Immunology
VU0514009 is a competitive chemokine-like receptor 1 (CMKLR1) antagonist (EC₅₀=2 nM). VU0514009 prevents chemerin-9-induced arrestin recruitment and receptor internalization, significantly reducing Ca ²⁺ flux response in HEK293 cells. VU0514009 is promising for research of inflammatory diseases and metabolic syndrome .

HY-43722

Lenalidomide-Br	Ligands for E3 Ligase	Cancer
Lenalidomide-Br (Compound 41) is an analog of cereblon (CRBN) ligand Lenalidomide for E3 ubiquitin ligase, and is used in the recruitment of CRBN protein. Lenalidomide-Br can be connected to the ligand for protein by a linker to form PROTACs, such as the PROTAC STAT3 degrader SD-36 (HY-129602) .

HY-119486A

(Rac)-Tavapadon (Rac)-PF-06649751; (Rac)-CVL-751	Dopamine Receptor Arrestin	Neurological Disease
(Rac)-Tavapadon ((Rac)-PF-06649751) is a potent and selective noncatechol dopamine D1 receptor agonist. (Rac)-Tavapadon displays potent full agonism in the GS activation assay as well as partial agonism in the β-arrestin2 recruitment assay (GS-cAMP, EC₅₀=0.8 nM; β-arrestin2, EC₅₀=68 nM). (Rac)-Tavapadon has antiparkinsonian activity .

HY-176446

Mrgx2 antagonist-3	Mas-related G-protein-coupled Receptor (MRGPR)	Inflammation/Immunology
Mrgx2 antagonist-3 (Compound B-40) is a highly selective antagonist of MrgX2 receptor with an IC₅₀ value of 0.042-2.5 nM. Mrgx2 antagonist-3 blocks downstream G protein signaling and β-Arrestin recruitment, thereby inhibiting MrgX2 receptor-mediated calcium influx and cellular degranulation. Mrgx2 antagonist-3 is promising for research of inflammation-related diseases and pruritus, such as chronic urticaria, allergic asthma .

HY-11067

WHI-P97 1 Publications Verification	JAK	Inflammation/Immunology
WHI-P97 is a potent and selective JAK-3 inhibitor. WHI-P97 is effective in preventing the development allergic asthma in vivo .

HY-145282

MS170 1 Publications Verification	PROTACs Akt	Cancer
MS170 is a potent and selective PROTAC AKT degrader. MS170 depletes cellular total AKT (T-AKT) with the DC₅₀ value of 32 nM. MS170 binds to AKT1, AKT2, and AKT3 with K_ds of 1.3 nM, 77 nM, and 6.5 nM, respectively .

HY-N3196

Neotuberostemonine	Bacterial	Infection Inflammation/Immunology
Neotuberostemonine, one of the main antitussive alkaloids in the root of Stemona tuberosa Lour, attenuates bleomycin-induced pulmonary fibrosis by suppressing the recruitment and activation of macrophages .

HY-115878

NJH-2-057	CFTR	Others
NJH-2-057 is an EN523 OTUB1 recruiter linked to lumacaftor, a agent used to treat cystic fibrosis that binds ΔF508-CFTR.

HY-W076696

3-(4-Hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione	Ligands for E3 Ligase	Cancer
Lenalidomide-4-OH is the Lenalidomide-based cereblon (CRBN) ligand used in the recruitment of CRBN protein. Lenalidomide-4-OH can be connected to the ligand for protein by a linker to form PROTAC.

HY-123109

(S,R,S)-AHPC-Boc VH032-Boc	Ligands for E3 Ligase	Cancer
(S,R,S)-AHPC-Boc (VH032-Boc) is a ligand used in the recruitment of the von Hippel-Lindau (VHL) protein. (S,R,S)-AHPC-Boc is used in PROTAC technology .

HY-138881

Lenalidomide-6-F	Ligands for E3 Ligase	Cancer
Lenalidomide-6-F is the Lenalidomide-based cereblon (CRBN) ligand used in the recruitment of CRBN protein. Lenalidomide-6-F can be connected to the ligand for protein by a linker to form PROTAC .

HY-143344

NJH-2-056	PROTACs CFTR	Inflammation/Immunology
NJH-2-056 is a deubiquitinase-targeting chimera (DUBTAC) linking the OTUB1 recruiter EN523 to the CFTR chaperone lumacaftor. NJH-2-056 can be used for cystic fibrosis research .

HY-156157

GPR55 agonist 4	GPR55	Cancer
GPR55 agonist 4 (Compound 28) is a GPR55 agonist (EC₅₀: 131 nM, and 1.41 nM for hGPR55 and rGPR55). GPR55 agonist 4 induces β-arrestin recruitment to human GPR55 .

HY-156107

GPR55 agonist 3	GPR55	Cancer
GPR55 agonist 3 (Compound 26) is a GPR55 agonist (EC₅₀: 0.239 nM, and 1.76 nM for hGPR55 and rGPR55). GPR55 agonist 3 induces β-arrestin recruitment to human GPR55 (EC₅₀: 6.2 nM) .

HY-175358

PROTAC USP7 Degrader-1	PROTACs Deubiquitinase	Cancer
PROTAC USP7 Degrader-1 is a *VHL*-recruiting PROTAC and USP7 degrader with binding activity to both USP7 and the VHL E3 ubiquitin ligase. PROTAC USP7 Degrader-1 recruits the VHL E3 ligase to mediate the ubiquitination and subsequent proteolytic degradation of USP7 .

HY-161166

MM-02-57	Others	Others
MM-02-57 is a covalent DDB1 CUL4A adaptor protein recruiter .

HY-143348

NJH-2-030	E3 Ligase Ligand-Linker Conjugates	Others
NJH-2-030 can be used as a covalent recruiter for FEM1B in targeted protein degradation applications.

HY-130991

K-Ras ligand-Linker Conjugate 6	Target Protein Ligand-Linker Conjugates	Cancer
K-Ras ligand-Linker Conjugate 6 incorporates a ligand for K-Ras recruiting moiety, and a PROTAC linker, which recruit E3 ligases (such as VHL, CRBN, MDM2, and IAP). K-Ras ligand-Linker Conjugate 6 can be used in the synthesis of PROTAC K-Ras Degrader-1 (HY-129523), which is potent PROTAC K-Ras degrader that exhibits ≥70% degradation efficacy in SW1573 cells .

HY-132808

Atuzabrutinib SAR 444727; PRN473	Btk	Inflammation/Immunology
Atuzabrutinib (SAR 444727) is a potent, selective reversible inhibitor of Btk (Bruton's tyrosine kinase) inhibitor. Atuzabrutinib inhibits neutrophil recruitment via inhibition of macrophage antigen-1 signalling .

HY-W244728

Desamino lenalidomide-pinacolborane	Ligands for E3 Ligase	Cancer
Desamino lenalidomide-pinacolborane is an E3 ubiquitin ligase cereblon (CRBN) ligand used to recruit the cereblon protein. Desamino lenalidomide-pinacolborane can be linked to a target protein ligand via a linker to form a PROTAC.

HY-160241

Lenalidomide-C5-acid	E3 Ligase Ligand-Linker Conjugates	Cancer
Lenalidomide-C5-acid is the Lenalidomide-based E3 ligase ligand-linker conjugate used in the recruitment of CRBN protein. Lenalidomide-C5-acid can be used to synthesize PROTACs .

HY-161408A

iGePhos1	PhosTACs Phosphatase	Others
iGePhos1 is an inactive GePhos1 (HY-161408) epimer used as a nonbinding negative control. iGephos1 lacks the phosphatase recruiting possibility .

HY-118521

AS-041164	PI3K	Inflammation/Immunology
AS-041164 is a potent, selective and orally active PI3Kγ isoform inhibitor with an IC₅₀ of 70 nM. AS-041164 shows less activity against PI3Kα, PI3Kβ, and PI3Kδ (IC₅₀s of 240 nM, 1.45 μM, and 1.70 μM, respectively). AS-041164 has anti-inflammatory effects .

HY-139544

Thalidomide-5-propoxyethanamine	E3 Ligase Ligand-Linker Conjugates Autophagy Apoptosis	Cancer
Thalidomide-5-propoxyethanamine is the Thalidomide-based cereblon (CRBN) ligand used in the recruitment of CRBN protein .

HY-P10563

Noraramtide BHV-1100	CD38	Cancer
Noraramtide (BHV-1100) is an antibody recruitment molecule. Noraramtide can specifically bind to CD38 molecules to recruit natural killer (NK) cells. Noraramtide enhances the ability of NK cells to kill tumor cells through antibody-dependent cellular cytotoxicity (ADCC). This mechanism allows NK cells to more effectively recognize and eliminate tumor cells while avoiding mutual killing between NK cells. Noraramtide can be used for the study of autologous cancer immunity .

HY-115575

tBPC	Neuropeptide Y Receptor	Metabolic Disease
tBPC is a selective positive allosteric modulator for human Y4 receptor (Y4R), which enhances the activation of Y4R in G protein signaling and arrestin3 recruitment .

HY-W586342

Desamino lenalidomide-COOH	Ligands for E3 Ligase	Cancer
Desamino lenalidomide-COOH is an E3 ubiquitin ligase cereblon (CRBN) ligand used to recruit the cereblon protein. Desamino lenalidomide-COOH can be linked to a target protein ligand via a linker to form a PROTAC.

HY-W580776

Desamino lenalidomide-cyano	Ligands for E3 Ligase	Cancer
Desamino lenalidomide-cyano is an E3 ubiquitin ligase cereblon (CRBN) ligand used to recruit the cereblon protein. Desamino lenalidomide-cyano can be linked to a target protein ligand via a linker to form a PROTAC.

HY-W998267

Desamino lenalidomide-Bpin	Ligands for E3 Ligase	Cancer
Desamino lenalidomide-Bpin is an E3 ubiquitin ligase cereblon (CRBN) ligand used to recruit the cereblon protein. Desamino lenalidomide-Bpin can be linked to a target protein ligand via a linker to form a PROTAC.

HY-138882A

Lenalidomide-4-aminomethyl hydrochloride	Ligands for E3 Ligase	Cancer
Lenalidomide-4-aminomethyl hydrochloride is the Lenalidomide-based cereblon (CRBN) ligand used in the recruitment of CRBN protein. Lenalidomide-4-aminomethyl hydrochloride can be connected to the ligand for protein by a linker to form PROTAC

HY-133137

SJF620	PROTACs Btk	Cancer
SJF620 is a PROTAC connected by ligands for Cereblon and Btk with a DC₅₀ of 7.9 nM. SJF620 contains a Lenalidomide analog for recruiting CRBN .

HY-175306

GPR183 inverse agonist-1	EBI2/GPR183 Arrestin	Inflammation/Immunology Cancer
GPR183 inverse agonist-1 (Compound 78) is a GPR183 inverse agonist. GPR183 inverse agonist-1 inhibits the GPR183-mediated Gi activation and β-arrestin2 recruitment, and blocks PBMC migration. GPR183 inverse agonist-1 can be used for inflammatory, autoimmune and neoplastic disorders research .

HY-175504

MLS6357	Dopamine Receptor PERK	Neurological Disease
MLS6357 is a D3 dopamine receptor (D3R)-selective positive allosteric modulator (PAM)-antagonist. MLS6357 exhibits antagonist activity in the D3R-mediated and the BRET-based β-arrestin recruitment assay with IC₅₀s of 13 and 14 μM, and no activity for other DAR subtypes (D1R/D2R/D4R/D5R) (IC₅₀ > 100 μM). MLS6357 is also an antagonist in the D3R-mediated Go-BRET assay with an IC₅₀ of 17 μM. MLS6357 can be used for the study of neuropsychiatric disorders, including substance use disorder .

Cat. No.	Product Name

HY-L024

Histone Modification Research Compound Library

904 compounds

A histone modification, a covalent post-translational modification (PTM) to histone proteins, includes methylation, phosphorylation, acetylation, ubiquitylation, and sumoylation, etc. In general, histone modifications are catalyzed by specific enzymes that act predominantly at the histone N-terminal tails involving amino acids such as lysine or arginine, as well as serine, threonine, tyrosine, etc. The PTMs made to histones can impact gene expression by altering chromatin structure or recruiting histone modifiers. Histone modifications act in diverse biological processes such as transcriptional activation/inactivation, chromosome packaging, and DNA damage/repair. Deregulation of histone modification contributes to many diseases, including cancer and autoimmune diseases.

MCE owns a unique collection of 904 bioactive compounds targeting Epigenetic Reader Domain, HDAC, Histone Acetyltransferase, Histone Demethylase, Histone Methyltransferase, Sirtuin, etc. Histone Modification Research Compound Library is a useful tool for histone modification research and drug screening.

HY-L129

Target Protein Ligand Library

94 compounds

Proteolysis-targeting chimera (PROTAC) has been developed to be a useful technology for targeted protein degradation. PROTACs consist of a ligand for E3 ligase (E3 ligase binder), a linker and a ligand (mostly small-molecule inhibitor) for protein of interest（target binder）. Upon binding to the target protein, the PROTACs can recruit E3 for target protein ubiquitination, which is subjected to proteasome-mediated degradation. Therefore, PROTACs execute their functions by degrading the target proteins rather than inhibiting them, which has a great superiority in overcoming resistance caused by target mutation or overexpression. To date, PROTAC technology has been applied to a variety of targets, including AR, ER, BTK, BET, and BCR-ABL to overcome resistance.

MCE carefully prepared a unique collection of 94 ligands for target proteins, which have been reported to be used in PROTAC design. MCE Target Protein Ligand Library is a useful tool for PROTAC development.

HY-L128

E3 Ligase Ligand Library

174 compounds

Although there are more than 600 E3 ubiquitin ligases, only several with small molecule ligands have been used for designing PROTACs, including Skp1-Cullin-F box complex containing Hrt1 (SCF), Von Hippel-Lindau tumor suppressor (VHL), Cereblon (CRBN), inhibitor of apoptosis proteins (IAPs), and mouse double minute 2 homolog (MDM2).

MCE carefully prepared a unique collection of 174 ligands for E3 ligase, which have been reported to be used in PROTAC design. MCE E3 ligase ligand library is a useful tool for PROTAC development.

HY-L918

Molecular Glue-like Compound Library

317 compounds

Targeted Protein Degradation (TPD) is a novel and promising approach to drug development. It shows great potential for targeting proteins traditionally considered "undruggable" due to the lack of enzymatic function and absence of binding sites by tagging them for degradation or recruiting natural degradation mechanisms.

Molecular glues are a type of small-molecule degraders that primarily induce novel interactions between E3 ubiquitin ligases and target proteins, forming ternary complexes that lead to protein ubiquitination and subsequent proteasomal degradation. Compared with PROTACs, molecular glues generally have lower molecular weights, higher cell permeability, and better drug-like properties. Additionally, the design of molecular glues is relatively simple, without the requirements for complex linkers and ligand optimization. As a result, molecular glues have gradually emerged as a promising therapeutic approach for various diseases.

Multiple types of molecular glues have been reported previously. Analysis of co-crystal complex structures reveals that CRBN-related molecular glues are more versatile. Therefore, MCE researchers select active molecules related to these targets as probes for artificial intelligence (AI) screening.Subsequently, molecular docking technology was used to verify whether the screened molecules retained the key pharmacophore features. Ultimately, we obtained 317 molecular glue analogs, and these compounds serve as powerful tools for the research of molecular glues.

Cat. No.	Product Name	Type

HY-W127575

Cholesta-3,5-diene

delta-3,5-Cholestadiene

Biochemical Assay Reagents

Cholesta-3,5-diene is an inflammatory modulator that targets immune cells such as neutrophils and accelerates wound healing by promoting neutrophil chemotaxis and fibroblast migration. Cholesta-3,5-diene enhances immune cell recruitment and extracellular matrix deposition by activating chemokine receptor-mediated signaling pathways such as PI3K/Akt. Cholesta-3,5-diene can be applied topically to wound repair and has potential therapeutic value in chronic ulcers or skin lesions .

HY-125474

Carrageenan

1 Publications Verification

Biochemical Assay Reagents

Carrageenan is an antiviral and anticancer agent. Carrageenan inhibits herpes simplex virus (HSV), HIV, and hepatitis A virus (HAV) by directly binding to the viral capsid to block the attachment of viruses such as HPV to HSPG factors on the cell surface. Carrageenan delays and arrests cell cycle progression, exhibits cytotoxicity against HeLa cancer cells, and can be applied to studies related to cervical cancer, genital warts, hepatitis A, and other conditions. Carrageenan also induces acute non-immune inflammation, triggers a three-phase inflammatory response involving the release of multiple proinflammatory mediators, and causes persistent edema, hyperalgesia, and neutrophil recruitment in mice .

HY-158226

Elastin Methacrylated

ElaMA

Biochemical Assay Reagents

Elastin Methacrylated (ElaMA) elastin recruits and modulates innate immune cells and accelerates angiogenesis at the wound site, thereby improving wound regeneration. Elastin Methacrylated attracts large numbers of neutrophils and primarily M2 macrophages to the wound and induces their penetration into the hydrogel. Elastin Methacrylated has excellent immunomodulatory effects, leading to superior angiogenesis, collagen deposition and dermal regeneration . Elastin Methacrylated needs to self-assemble into fibrous hydrogel under the action of photoinitiator LAP (HY-44076), and target bioactive adhesion sites, play an inherent supporting role for tissue cells and biodegradable activity.
Application: cell culture, biological 3D printing, tissue engineering, etc.

HY-NP216

PA-IIL

LecB

Biochemical Assay Reagents

PA-IIL (LecB) is a lectin produced by Pseudomonas aeruginosa. PA-IIL binds to glycosylated β1-integrin, fucose-containing glycosphingolipids, fucosylated/mannosylated neutrophil glycoconjugates, and pre-formed neutrophil extracellular traps. PA-IIL disrupts host defenses: it creates favorable conditions for Pseudomonas aeruginosa infection and dissemination by modulating the bactericidal activity of neutrophils, impairing the trafficking and recruitment of immune cells, and compromising the repair capacity of epithelial barriers. PA-IIL can be used in studies related to Pseudomonas aeruginosa infection .

Cat. No.	Product Name	Target	Research Area

HY-108742

Abaloparatide 3 Publications Verification BA 058; BIM 44058	PTHR Arrestin	Metabolic Disease Cancer
Abaloparatide (BA 058) is a parathyroid hormone receptor 1 (PTHR1) analog. Abaloparatide also is a selective PTHR1 activator. Abaloparatide enhances Gs/cAMP signaling and β-arrestin recruitment. Abaloparatide enhances bone formation and cortical structure in mice. Abaloparatide has the potential for the research of osteoporosis .

HY-P3419

PAMP-12 (unmodified) 2 Publications Verification	Mas-related G-protein-coupled Receptor (MRGPR) PERK Calcium Channel	Cardiovascular Disease Inflammation/Immunology
PAMP-12 (unmodified) is an endogenous peptide and is a MrgX2 agonist. PAMP-12 (unmodified) can reduce cAMP accumulation, increase Ca ²⁺levels, enhance beta-arrestin recruitment, decrease IP-1, and increases phosphoERK. PAMP-12 (unmodified) can elicit hypotension through inhibiting catecholamine secretion from sympathetic nerve endings and adrenal chromaffin cells. PAMP-12 (unmodified) can be used for the research of hypotension and ulcerative colitis .

HY-P10408

Candidalysin	EGFR MMP Calcium Channel NOD-like Receptor (NLR) ERK p38 MAPK	Infection Inflammation/Immunology
Candidalysin is a cytolytic peptide toxin secreted by the fungus Candida albicans. Candidalysin drives epithelial immune responses by activating the EGFR-MAPK signaling pathway, inducing MMP expression and calcium influx, and regulating the c-Fos transcription factor and MKP1 via p38 MAPK and ERK1/2 respectively. Candidalysin is essential for mucosal and systemic infections, activating NLRP3 to promote inflammatory responses, neutrophil recruitment, and Th17 immunity. Candidalysin activates LDH causing membrane damage and exhibiting cytotoxicity

HY-P1680

Astin C Asterin	STING HSV	Infection Inflammation/Immunology Cancer
Astin C (Asterin) is a cyclopeptide that can be extracted from Aster tataricus. Astin C has anti-inflammatory and anti-cancer activities. Astin C can specifically inhibit the cGAS-STING signaling pathway, block the recruitment of IRF3 to the STING signalosome, and thus inhibit the innate inflammatory response. Astin C can be used in the research of autoimmune diseases and cancers .

HY-122542B

PPACK TFA 2 Publications Verification	Ligands for E3 Ligase Molecular Glues IKZF Family	Cardiovascular Disease
PPACK TFA is an orally active, selective molecular glue degrader targeting IKZF2. Through a molecular glue mechanism, PPACK TFA binds to CRBN, recruits IKZF2 to form a ternary complex, and promotes its ubiquitination and proteasomal degradation. This further converts inhibitory regulatory T cells (T_reg) into effector-like T cells, enhances CD8 ⁺ T cell responses, and modulates the T_eff:T_reg balance. PPACK TFA also increases the production of the inflammatory cytokine IL-2 and reduces the suppressive activity of T_reg. PPACK TFA can be used in cancer immunotherapy research, and exhibits a synergistic effect when combined with immune checkpoint inhibitors such as anti-PD1 .

HY-P1682A

Balixafortide TFA 1 Publications Verification POL6326 TFA	CXCR Arrestin	Cancer
Balixafortide TFA (POL6326 TFA) is a potent, selective, well-tolerated peptidic CXCR4 antagonist with an IC₅₀ < 10 nM. Balixafortide TFA shows 1000-fold selective for CXCR4 than a large panel of receptors including CXCR7. Balixafortide TFA blocks β-arrestin recruitment and calcium flux with IC₅₀s < 10 nM. Balixafortide TFA is also a potent hematopoietic stem and progenitor cell (HSPC) mobilizing agent. Anti-cancer effects .

HY-P1102

TC14012 4 Publications Verification	CXCR HIV	Infection Cancer
TC14012, a serum-stable derivative of T140, is a selective and peptidomimetic CXCR4 antagonist with an IC₅₀ of 19.3 nM. TC14012 is a potent CXCR7 agonist with an EC₅₀ of 350 nM for recruiting β-arrestin 2 to CXCR7. TC14012 has anti-HIV activity and anti-cancer activity .

HY-P1682

Balixafortide 1 Publications Verification POL6326	CXCR Arrestin	Cancer
Balixafortide (POL6326) is a potent, selective, well-tolerated peptidic CXCR4 antagonist with an IC₅₀ < 10 nM. Balixafortide shows 1000-fold selective for CXCR4 than a large panel of receptors including CXCR7. Balixafortide blocks β-arrestin recruitment and calcium flux with IC₅₀s < 10 nM. Balixafortide is also a potent hematopoietic stem and progenitor cell (HSPC) mobilizing agent. Anti-cancer effects .

HY-P2197

ELA-11(human)	Apelin Receptor (APJ) Arrestin	Inflammation/Immunology
ELA-11(human), a peptide, is a full agonist of human apelin receptor, with a pK_i of 7.85. ELA-11(human) completely inhibits Forskolin-induced cAMP production and stimulates β-arrestin recruitment .

HY-P10114

STAT3-IN-24, cell-permeable PpYLKTK-mts; STAT3 PI	STAT	Cancer
STAT3-IN-24, cell-permeable (PpYLKTK-mts) is a STAT3 peptide inhibitor. STAT3-IN-24, cell-permeable inhibits recruitment of STAT3 to Jak2 and phosphorylation of Y705, thus preventing the dimerization and the nuclear translocation of STAT3 .

HY-108742A

Abaloparatide TFA 3 Publications Verification BA 058 TFA; BIM 44058 TFA	Arrestin PTHR	Metabolic Disease Endocrinology Cancer
Abaloparatide TFA (BA 058 TFA) is a parathyroid hormone receptor 1 (PTHR1) analogue. Abaloparatide TFA also is a selective PTHR1 activator. Abaloparatide TFA enhances Gs/cAMP signaling and β-arrestin recruitment. Abaloparatide TFA enhances bone formation and cortical structure in mice. Abaloparatide TFA has the potential for the research of osteoporosis .

HY-P3012

Cathepsin G	Cathepsin ERK p38 MAPK PKC Protease Activated Receptor (PAR) MMP	Inflammation/Immunology
Cathepsin G is a pH-dependent serine protease. Cathepsin G hydrolyzes diverse synthetic and protein substrates and remodels extracellular matrix. Cathepsin G exerts immunomodulatory effects via recruiting phagocytes, enhancing T cell motility, activating ERK1/2 and p38 MAPK signaling, and mediating PKCζ membrane translocation. Cathepsin G regulates inflammatory responses by cleaving inflammatory mediators. Cathepsin G participates in vascular regulation by converting angiotensin I to angiotensin II. Cathepsin G induces PAR4-dependent platelet activation, facilitates platelet-neutrophil aggregation, and mediates VITT-related NETosis, thrombus formation. Cathepsin G can be used for the research of immune thrombotic thrombocytopenia, cardiovascular disease, and select autoimmune and inflammatory diseases .

HY-P10333A

LIH383 TFA	CXCR	Neurological Disease Inflammation/Immunology
LIH383 TFA is an agonist of ACKR3 (CXCR7) (EC₅₀=0.61 nM). LIH383 TFA efficiently induces the recruitment of β-arrestin to ACKR3 but does not trigger typical G protein signaling .

HY-P5812

IDR 1002	Integrin	Inflammation/Immunology
IDR-1002 is an anti-infective peptide that enhances the ability of human monocytes to migrate toward chemokines on fibronectin. IDR-1002 also induces adhesion and activation of β1-integrin, a mechanism that promotes monocyte recruitment .

HY-P2249

ELA-21 (human)	Arrestin Apelin Receptor (APJ)	Cardiovascular Disease
ELA-21 (human) is an apelin receptor agonist with a pK_i of 8.52. ELA-21 (human) completely inhibits Forskolin-induced cAMP production and stimulates β-arrestin recruitment with subnanomolar potencies. ELA-21 (human) is an agonist in G-protein-dependent and -independent pathways .

HY-126327A

UNC4976 TFA	Histone Methyltransferase	Cancer
UNC4976 TFA is a positive allosteric modulator (PAM) peptidomimetic of CBX7 chromodomain binding to nucleic acids. UNC4976 TFA simultaneously antagonizes H3K27me3-specific recruitment of CBX7 to target genes while increasing non-specific binding to DNA and RNA .

HY-P10563

Noraramtide BHV-1100	CD38	Cancer
Noraramtide (BHV-1100) is an antibody recruitment molecule. Noraramtide can specifically bind to CD38 molecules to recruit natural killer (NK) cells. Noraramtide enhances the ability of NK cells to kill tumor cells through antibody-dependent cellular cytotoxicity (ADCC). This mechanism allows NK cells to more effectively recognize and eliminate tumor cells while avoiding mutual killing between NK cells. Noraramtide can be used for the study of autologous cancer immunity .

HY-126327

UNC4976	Histone Methyltransferase	Cancer
UNC4976 is a positive allosteric modulator (PAM) peptidomimetic of CBX7 chromodomain binding to nucleic acids. UNC4976 simultaneously antagonizes H3K27me3-specific recruitment of CBX7 to target genes while increasing non-specific binding to DNA and RNA .

HY-P11023

E16-uPA24	Peptides	Metabolic Disease Inflammation/Immunology Cancer
E16-uPA24 is a chimeric peptide targeting urokinase-type plasminogen activator receptor (uPAR). E16-uPA24 modifies senescent cells surface with polyglutamic acid, promoting immune cell-mediated responses through glutamate recognition. E16-uPA24 induces immune clearance of senescent cells and restores tissue homeostasis by enhancing immune cells recruitment and directly coupling senescent cells and immune cells. E16-uPA24 can be used for tissue degeneration, chronic inflammatory disease and age-related tumorigenesis research .

HY-P11272

Tasronetide FTX-101	VEGFR	Neurological Disease
Tasronetide (FTX-101) is a highly selective inhibitor toward the NRP1/Plexin-A1 receptor system, and displays no significant activity on other targets. Tasronetide intercalates within the transmembrane domains of Plexin-A1 and NRP1 of oligodendrocytes, interferes with the heterodimerization of the co-receptor system, effectively disrupts the NRP1/Plexin-A1 receptor complex and mitigates the inhibitory influence of Sema3A on oligodendrocyte migration and differentiation, thereby facilitating increased myelin sheathing around axons. Tasronetide is designed to enhance the recruitment and maturation of oligodendrocyte precursors and can be used for Chronic Op c Neuropathy research .

HY-P11493

ALAPYIP	Ligands for E3 Ligase	Cancer
ALAPYIP is a ligand for E3 ligase. ALAPYIP recruits the VHL-E3 ubiquitin ligase. ALAPYIP can be used for the synthesis of FPP29 (HY-P11228) .

HY-138951

AY77	Protease Activated Receptor (PAR)	Inflammation/Immunology Cancer
AY77 is a calcium-biased PAR2 agonist. AY77 shows an EC₅₀ of 0.17 and 2 nM in PAR2-mediated the activation in the Gq pathway and recruitment of β-arrestin-2, respectively. AY77 potently induces intracellular Ca ²⁺ release .

HY-P11553

ECL1i	CCR	Inflammation/Immunology
ECL1i is an allosteric, selective CCR2 inhibitor. ECL1i specifically inhibits CCL2-/CCR2-mediated chemotaxis. ECL1i interferes with CCR2-positive cell recruitment and attenuates disease progression in experimental autoimmune encephalomyelitis .

HY-P11553A

ECL1i TFA	CCR	Infection Inflammation/Immunology
ECL1i TFA is an allosteric, selective CCR2 inhibitor. ECL1i TFA specifically inhibits CCL2-/CCR2-mediated chemotaxis. ECL1i TFA interferes with CCR2-positive cell recruitment and attenuates disease progression in experimental autoimmune encephalomyelitis .

HY-P1102A

TC14012 TFA	CXCR HIV	Infection Cancer
TC14012 TFA, a serum-stable derivative of T140, is a selective and peptidomimetic CXCR4 antagonist with an IC₅₀ of 19.3 nM. TC14012 TFA is a potent CXCR7 agonist with an EC₅₀ of 350 nM for recruiting β-arrestin 2 to CXCR7. TC14012 TFA has anti-HIV activity and anti-cancer activity .

HY-P10870

Pep1-DNP conjugate 9	Peptide-Drug Conjugates (PDCs) FGFR Apoptosis	Cancer
Pep1-DNP conjugate 9 is a functionalized peptide which is composed of the DNP-Hapten and the FGFR1 binding peptide. Pep1-DNP conjugate 9 exhibits good affinity to FGFR1 with K_D of 5.01 μM. Pep1-DNP conjugate 9 recruits anti-DNP antibodies to the surface of FGFR1-positive cells, inhibits the FGF2-induced proliferation in rat skeletal myoblast cells, and induces apoptosis. Pep1-DNP conjugate 9 exhibits antitumor efficacy in mouse models .

HY-P11246

A13:B7-24-GG	RXFP Receptor	Metabolic Disease
A13:B7-24-GG is an engineered analogue of insulin-like peptide 5 (INSL5), a selective RXFP4 agonist with a K_i value of 2.29 nM. A13:B7-24-GG has an extremely low binding affinity for RXFP3 (K_i = 602.56 nM) and an inhibitory effect on cAMP (EC₅₀) of 1.17 nM. Activation of RXFP4 by A13:B7-24-GG leads to the recruitment of β-Arrestin2, with an EC₅₀ of 22.39 nM. A13:B7-24-GG can be used for research on chronic constipation .

HY-P4272

Tetraproline	Peptides	Others
Tetraproline is a fragment sequence in tristetraprolin (TTP). Recruitment of the 4EHP-GYF2 cap-binding complex to tetraproline motifs of tristetraprolin promotes repression and degradation of mRNAs with AU-rich elements .

HY-P10333

LIH383	CXCR	Neurological Disease Inflammation/Immunology
LIH383 is an agonist of ACKR3 (CXCR7) (EC₅₀=0.61 nM). LIH383 efficiently induces the recruitment of β-arrestin to ACKR3 but does not trigger typical G protein signaling .

HY-P1099

Ac2-12 1 Publications Verification	Peptides	Inflammation/Immunology
Ac2-12, an annexin/lipocortin 1 (LC1)-mimetic peptide, inhibit neutrophil extravasation. Ac2-12 has antimigratory action and inhibits recruitment of neutrophils in experimental inflammation models .

HY-P1099A

Ac2-12 TFA	Peptides	Inflammation/Immunology
Ac2-12 TFA, an annexin/lipocortin 1 (LC1)-mimetic peptide, inhibit neutrophil extravasation. Ac2-12 TFA has antimigratory action and inhibits recruitment of neutrophils in experimental inflammation models .

HY-P11275

TC4	GLP Receptor GCGR Neuropeptide Y Receptor	Metabolic Disease
TC4 is a highly balanced single-molecule quadruple agonist that can respectively activate GIPR, GLP-1R, GcgR, and Y2R with IC₅₀ values of 0.95, 31, 81, and 1100 nM respectively. TC4 exhibits extremely strong signal bias on GLP-1R and has very low recruitment efficacy for β-inhibitor protein 2 (βArr2) and this strong cAMP preference is believed to maximize metabolic benefits (such as weight loss and hypoglycemia) while possibly minimizing side effects mediated by β-inhibitor protein recruitment (such as receptor desensitization). TC4 can be used for research on obesity and diabetes .

HY-P2197A

ELA-11(human) TFA	Apelin Receptor (APJ)	Inflammation/Immunology
ELA-11(human) TFA is a high affinity apelin receptor agonist (K_i=14 nM). ELA-11(human) TFA is a bioactive fragment of ELA-32. ELA-11(human) TFA inhibits forskolin-induced cAMP production and stimulates β-arrestin recruitment in vitro.

HY-P11279

TC2	GLP Receptor GCGR Neuropeptide Y Receptor	Metabolic Disease
TC2 is an efficient GIPR-preferring monomeric quadruple agonist that can respectively activate GIPR, GLP-1R, GcgR, and Y2R with IC₅₀ values of 0.47, 2.1, 30, and 55 nM respectively. TC2 exhibits a significant GLP-1R preference, with a significant reduction in β-inhibitory protein 2 (βArr2) recruitment, while maintaining a strong cAMP signal. TC2 can be used for research on obesity and diabetes .

HY-P3419A

PAMP-12 (unmodified) TFA	Mas-related G-protein-coupled Receptor (MRGPR) PERK Calcium Channel	Cardiovascular Disease Inflammation/Immunology
PAMP-12 (unmodified) TFA is an endogenous peptide and is a MrgX2 agonist. PAMP-12 (unmodified) TFA can reduce cAMP accumulation, increase Ca ²⁺levels, enhance beta-arrestin recruitment, decrease IP-1, and increases phosphoERK. PAMP-12 (unmodified) TFA can elicit hypotension through inhibiting catecholamine secretion from sympathetic nerve endings and adrenal chromaffin cells. PAMP-12 (unmodified) TFA can be used for the research of hypotension and ulcerative colitis .

HY-P11298

d-T101 peptide	Caspase Apoptosis JNK p38 MAPK Interleukin Related IFNAR	Inflammation/Immunology Cancer
d-T101 peptide, a human hormone-peptide, is a T1/ST2 receptor ligand. d-T101 peptide binds to the T1/ST2 receptor and activates caspases 8, 9 and 3 mediated apoptosis, together with activation of JNKinase and p38 MAPKinase. d-T101 peptide also changes Golgi structural with function loss and downregulation of the endoplasmic reticulum (ER) stress repair mechanism. d-T101 peptide has immunostimulatory and anticancer activity, selectively induces apoptosis in proliferating cancer cells and increases IL-2 and IFN-γ expression as well as the recruitment of NK cells and M1 macrophages to the tumor site .

HY-P1345B

[DArg10, DAla20] TLQP-21	Complement System Calcium Channel Drug Derivative	Neurological Disease Metabolic Disease Inflammation/Immunology
[DArg10, DAla20] TLQP-21, TLQP-21 (HY-P1345) analogue, is a C3aR agonist (EC₅₀: 87 nM for β-arrestin recruitment). [DArg10, DAla20] TLQP-21 elicits calcium influx. [DArg10, DAla20] TLQP-21 slightly but not significantly potentiates adrenergic-induced lipolysis. [DArg10, DAla20] TLQP-21 can be used in the research of inflammatory diseases, metabolic disorders, and neurological conditions .

HY-P11728

Peptide E5	CXCR Apoptosis Caspase Akt ERK	Cancer
Peptide E5 is an antagonist targeting the CXCR4/CXCL12 axis. Peptide E5 blocks the CXCR4/CXCL12 axis, downregulates CXCR4 expression, and inhibits the phosphorylation of downstream Akt and Erk. Peptide E5 induces apoptosis, suppresses migration and adhesion of breast cancer cells. Peptide E5 inhibits CXCL12-mediated endothelial progenitor cell recruitment, thereby suppressing tumor angiogenesis. Peptide E5 is applicable to relevant research on breast cancer .

HY-P1345C

[DArg10, Aib20] TLQP-21	Drug Derivative Complement System	Neurological Disease Metabolic Disease Inflammation/Immunology
[DArg10, Aib20] TLQP-21, TLQP-21 (HY-P1345) analogue, is a C3aRpartial agonist, C3aR functional antagonist (EC₅₀: 854 nM for β-arrestin recruitment). [DArg10, Aib20] TLQP-21 shows no significant calcium flux activity. [DArg10, Aib20] TLQP-21 shows no activity in potentiating adrenergic-induced lipolysis. [DArg10, Aib20] TLQP-21 can be used in the research of inflammatory diseases, metabolic disorders, and neurological conditions .

HY-182539

DD04107	CGRP Receptor	Others Neurological Disease
DD04107 is a neuronal exocytosis inhibitor with a rat Syt1-C2B domain binding K_a of 2.4 μM. DD04107 interferes with synaptobrevin-syntaxin-SNAP-25 complex formation and Syt1-SNARE complex interaction to block α-calcitonin gene-related peptide (α-CGRP) exocytotic release from primary sensory neurons. DD04107 blocks inflammatory ion channel recruitment to nociceptor plasma membranes. DD04107 can be used for the research of chronic inflammatory pain, neuropathic pain, osteosarcoma pain, chemotherapy-induced peripheral neuropathy, diabetic neuropathy, inflammatory pain .

Cat. No.	Product Name	Target	Research Area	Image

HY-P99361

Enavatuzumab PDL192; ABT-361; Anti-TNFRSF12A/TWEAKR/CD266 Reference Antibody (enavatuzumab)	TNF Receptor	Cancer
Enavatuzumab (PDL192; ABT-361) is a humanized IgG1 monoclonal antibody targeting the receptor of TNF-like weak inducer of apoptosis (TWEAK). TWEAK (Fn14; TNFRSF12A), the natural ligand of the TWEAK receptor (TweakR), stimulates multiple cellular responses. Enavatuzumab induces tumor growth inhibition through direct TweakR signaling and antibody dependent cell-mediated cytotoxicity (ADCC). Enavatuzumab can actively recruits and activates myeloid effectors to kill tumor cells. Enavatuzumab inhibits the growth of various human TweakR-positive cancer cell lines and xenografts in vitro and in vivo .

HY-P990688

Xaluritamig AMG-509	CD3	Cancer
Xaluritamig (AMG-509) is a bispecific T cell engager and cytolytic agent with a K_d of 27.6 nM for human CD3ε. Xaluritamig binds to CD3ε via an anti-CD3 single-chain variable fragment (scFv) domain, and to STEAP1 via a bispecific anti-STEAP1 antigen-binding fragment (Fab) domain, thereby recruiting and activating T cells and forming a bridge between T cells and STEAP1-expressing cancer cells. Xaluritamig induces T cell-mediated redirected cytotoxicity, tumor cell lysis, cytokine release, CD8 ⁺ T cell activation and expansion, as well as tumor stasis or regression. Xaluritamig contains an Fc domain with no effector function, which prolongs serum half-life, exhibits only minimal activity against cells with low STEAP1 expression and normal cells, and shows extremely low target-related off-tumor toxicity in cynomolgus monkeys. Xaluritamig is used in STEAP1×CD3 XmAb 2+1 immunotherapy and in research on metastatic castration-resistant prostate cancer and Ewing sarcoma .

HY-P99394

Talquetamab 1 Publications Verification JNJ-64407564	CD3	Cancer
Talquetamab (JNJ-64407564) is a humanized bispecific antibody that binds to GPRC5D (member of G protein-coupled receptor family C5 group D) and CD3 to induce T cell-mediated killing of GPRC5D-expressing MM cells through T cell recruitment and activation. Talquetamab (JNJ-64407564) has antitumor activity .

HY-P99430

Alnuctamab EM901; CC-93269	CD3	Inflammation/Immunology Cancer
Alnuctamab (EM901) is a bispecific T-cell engager targeting BCMA and CD3, belonging to an asymmetric two-armed humanized IgG1 antibody. Alnuctamab can simultaneously bind to BCMA expressed on the surface of myeloma cells and CD3 molecules on the surface of T cells, recruiting T cells to kill tumors. Alnuctamab is used for the research of multiple myeloma. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P99781

Plozalizumab MLN-1202	CCR	Inflammation/Immunology Cancer
Plozalizumab (MLN-1202) is a humanized anti-CCR2 IgG1 monoclonal antibody. Plozalizumab blocks the recruitment of myeloid cells to the tumor microenvironment by inhibiting the CCL2/CCR2 axis. In addition, Plozalizumab also ameliorates synovial inflammation in rheumatoid arthritis. Plozalizumab can be used in the research of malignant melanoma and bone metastasis-related cancers. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P99776

Plamotamab XmAb-13676	CD20 CD3	Cancer
Plamotamab (XmAb-13676) is a human bispecific antibody (bsAb) that binds CD3 and CD20. Plamotamab recruits cytotoxic T cells to kill CD20 ⁺ expressing tumor cells. Plamotamab induces a mild hematologic reaction (MR), and results in tumor regression in vivo .

HY-P99916

Emirodatamab AMG-427	FLT3 CD3 TNF Receptor	Inflammation/Immunology Cancer
Emirodatamab (AMG-427) is a bispecific T-cell engager (BiTE). Emirodatamab simultaneously binds FLT3 on the surface of acute myeloid leukemia (AML) cells and CD3 on the surface of T cells, thereby precisely recruiting immune effector cells to tumor sites. Emirodatamab potently induces T cell activation, secretion of proinflammatory cytokines (such as IFNγ, TNFα), and specific cytotoxicity, effectively lysing FLT3-positive tumor cells and inhibiting their growth. Emirodatamab not only significantly prolongs survival in mouse xenograft models and eliminates diseased cells in primates, but also exhibits a synergistic enhancement effect when combined with PD-1 blockade therapy. Emirodatamab is used in studies of acute myeloid leukemia, especially relapsed or refractory cases .

HY-P99746

Murlentamab 3C23K; GM102	TGF-β Receptor	Inflammation/Immunology Cancer
Murlentamab (3C23K; GM102) is a humanized anti-AMHRII antibody. AMHRII is the anti-Müllerian hormone receptor. Murlentama significantly promotes macrophage-mediated antibody-dependent cell-mediated cytotoxicity (ADCC). Murlentama stimulates pro-inflammatory and anti-tumor internal environment, recruits and activates T cells. Murlentama suppresses tumors growth by inducing naïve macrophage orientation and promoting tumor-associated macrophage (TAM) reprogramming .

HY-P991042

Anti-IGFBP2 Antibody (M14)	IGF-1R	Cancer
Anti-IGFBP2 Antibody (M14) is an human anti-IGFBP2 monoclonal inhibitory antibody, which binds IGFBP2 with high affinity and blocks its binding with IGF1. Anti-IGFBP2 Antibody (M14) inhibits human endothelial cell recruitment, thus blocks the tumor progression of human metastatic cancer .

HY-P991181

VTX-1218	Transmembrane Glycoprotein	Cancer
VTX-1218 is a VSIG4 inhibitor with human K_d 7.4 nM. VTX-1218 blocks VSIG4 activity, relieves VSIG4-mediated macrophage suppression, repolarizes tumor-associated macrophages and induces T cell activation. VTX-1218 upregulates cytokines and chemokines linked to immune cell recruitment. VTX-1218 can be used for the research of multiple cancer types .

HY-P991545

BVX20	CD20	Cancer
BVX20 is a human monoclonal antibody that binds to CD20. BVX20 can kill B-cells through recruiting the immune system. BVX20 can be studied in research for relapsed or chemotherapy-resistant follicular B-cell NHL and CD20-positive diffuse large B-cell NHL .

HY-P991250

MSH-TP15e	Integrin	Cancer
MSH-TP15e is a humanized monoclonal antibody inhibitor targeting intercellular adhesion molecule-1 (ICAM-1). MSH-TP15e recruits natural killer cells and significantly triggers antibody-dependent cell-mediated cytotoxicity (ADCC) to inhibit tumor cell growth. MSH-TP15e is promising for research of multiple myeloma (MM) .

HY-P990801

Anti-Mouse CD11a/LFA-1α Antibody (M17/4)	Integrin Parasite Bacterial	Infection Neurological Disease Inflammation/Immunology Cancer
Anti-Mouse CD11a/LFA-1α Antibody (M17/4) is an anti-mouse CD11a/LFA-1α IgG2a monoclonal antibody. Anti-Mouse CD11a/LFA-1α Antibody (M17/4) can reduce the recruitment of effector memory CD8 T cells. Anti-Mouse CD11a/LFA-1α Antibody (M17/4) promotes the formation of xenograft tumors by reducing immune rejection reactions. Anti-Mouse CD11a/LFA-1α Antibody (M17/4) can be used for researches on cancer, infection conditions and immunology such as glioblastoma, parasitic and bacterial infections. The recommend isotype control of Anti-Mouse CD11a/LFA-1α Antibody (M17/4): Rat IgG2a kappa, Isotype Control (HY-P990679) .

HY-P992035

AMY109	Interleukin Related	Endocrinology
AMY109 is an anti-human interleukin-8 (IL-8) monoclonal antibody, with IC₅₀ values of 0.14 μg/mL and 0.37 μg/mL against human IL-8, a K_a of 36.8 pM for human IL-8, and a K_a of 380 pM for cynomolgus monkey IL-8.\nAMY109 binds to human and cynomolgus monkey IL-8 in a pH-dependent manner, inhibits IL-8-mediated activation of CXCR1 and CXCR2, and blocks the downstream biological activities of IL-8. AMY109 inhibits neutrophil recruitment to endometriotic lesions and suppresses monocyte chemoattractant protein-1 production by neutrophils. AMY109 is applicable to research related to endometriosis .

HY-P992153

Serrumab	Interleukin Related	Inflammation/Immunology
Serrumab is a human monoclonal antibody that counteracts the biochemical and immunological effects of Tityus serrulatus venom. Serrumab inhibits the TsV-induced increase in the production of IL-6, TNFα and IL-10. Serrumab also prevents TsV-induced elevations in plasma urea, creatinine, aspartate transaminase and glucose levels, as well as the TsV-induced increase in neutrophil recruitment. Serrumab can be used in research related to envenoming by the Brazilian yellow scorpion .

HY-P991957

PRN100	Prion Protein	Neurological Disease
PRN100 is a fully humanized monoclonal antibody against cellular prion protein (PrPᶜ), belonging to the IgG_4κ isotype. By binding to and stabilizing cellular prion protein, PRN100 is designed to prevent cellular prion protein from being recruited and converted into pathogenic, self-propagating prion (PrPˢᶜ) aggregates. PRN100 can be used for the study of Creutzfeldt-Jakob disease.

HY-P991761

Anti-Mouse CXCL10 Antibody (1F11)	CXCR	Inflammation/Immunology
Anti-Mouse CXCL10 Antibody (1F11) reacts with the pro-inflammatory CXCL10. Anti-Mouse CXCL10 Antibody (1F11) can be used for neutralization of CXCL10 (in vitro and in vivo) and for inhibition of T cell recruitment in vivo in a range of inflammatory disease models. Recommend Isotype Controls: Polyclonal Armenian hamster IgG, Isotype Control (HY-P990305) .

HY-P991773

Anti-Mouse CD11b Antibody (5C6)	Integrin	Inflammation/Immunology
Anti-Mouse CD11b Antibody (5C6) is a CD11b blocking antibody. Anti-Mouse CD11b Antibody (5C6) can be used for in vitro inhibition of myelomonocytic cell adhesion and in vivo inhibition of inflammatory cell recruitment. Recommend Isotype Controls: Rat IgG2b kappa, Isotype Control (HY-P990682) .

HY-P992043

Tolododekin alfa ANK-101	Interleukin Related PD-1/PD-L1	Inflammation/Immunology Cancer
Tolododekin alfa (ANK-101) is a drug conjugate that anchors and combines IL-12 with Aluminum Hydroxide (HY-B1521). Tolododekin alfa promotes the recruitment of effector CD8 ⁺T cells to tumor sites, enhances the production of γ-interferon, upregulates the expression of PD-L1, and induces sustained pro-inflammatory gene expression in mouse tumor models. Tolododekin alfa can be used for research related to advanced solid tumors .

HY-P992380

IBC-Ab002	PD-1/PD-L1	Neurological Disease
IBC-Ab002 is a humanized anti-PD-L1 monoclonal antibody with a modified Fc backbone that shortens its circulating half-life. IBC-Ab002 inhibits PD-L1, triggers immune responses by blocking the PD-1/PD-L1 pathway, promotes the recruitment of myeloid-derived immune cells to the brain, enhances the clearance of toxic substances in the brain, improves neuronal function and reduces inflammation. IBC-Ab002 reduces the risk of accelerated onset of autoimmune diabetes in susceptible mice. IBC-Ab002 can be used in research related to Alzheimer's disease .

HY-P991944

ZL-1218	CCR	Cancer
ZL-1218 is a selective humanized IgG1 antibody, targeting CCR8. ZL-1218 induces antibody-dependent cellular cytotoxicity (ADCC), leading to NK cell-mediated depletion of CCR8-expressing regulatory T cells (Tregs). ZL-1218 blocks the binding of the CCR8 ligand CCL1 to CCR8 and reduces Treg recruitment by inhibiting the chemotaxis of CCR8 ⁺ cells. ZL-1218 reduces intratumoral Treg levels in a dose-dependent manner. ZL-1218 exerts enhanced antitumor activity when combined with the anti-PD-1 antibody. ZL-1218 can be used for solid tumour research .

HY-P992401

M802	EGFR CD3 PI3K Akt p38 MAPK Caspase Apoptosis IFNAR TNF Receptor Interleukin Related	Cancer
M802 is an anti-HER2/CD3 bispecific antibody, with a K_d of 0.578 nM for human HER2 and a K_d of 71.2 nM for human CD3. M802 inhibits the PI3K/AKT and MAPK signaling pathways, suppresses tumor cell proliferation, activates caspase-3, and promotes tumor cell apoptosis (apoptosis). M802 recruits and activates CD3-positive immune cells, mediates cytotoxicity against HER2-positive tumor cells, and induces immune cells to secrete IFN-γ, TNF-α, IL-2 and IL-6. M802 exhibits anti-tumor efficacy in mice with gastric cancer xenografts. M802 can be used in research related to HER2-positive breast cancer, HER2-positive gastric cancer and other cancers. The recommended isotype control is human IgG1 kappa (HY-P99001) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-W012078

5-Methyl-2'-deoxycytidine 3 Publications Verification 5-Methyldeoxycytidine	Natural Products Classification of Application Fields Other Diseases Endogenous metabolite Disease Research Fields Source Classification	DNA Methyltransferase Endogenous Metabolite
5-Methyl-2'-deoxycytidine (5mdC) is an endogenous substrate of DNA methyltransferases (such as mammalian 5-C-MTase) and binds to DNA dependent on the formation of DNA stem-loop structures. 5-Methyl-2'-deoxycytidine guides de novo DNA methylation by acting as a methylation mark and activates the methylation of adjacent CpG sites in single-stranded DNA through cis action. 5-Methyl-2'-deoxycytidine regulates DNA methylation patterns by recruiting methyltransferases to specific chromatin regions, affecting chromatin condensation and gene expression. Its distribution in plant cells is related to cell proliferation and differentiation stages. The methylation level of 5-Methyl-2'-deoxycytidine is low in proliferating cells and high in differentiated cells .

HY-N0010

Geniposidic acid Maximum Cited Publications 7 Publications Verification	Structural Classification other families Iridoids Classification of Application Fields Terpenoids Plants Endogenous metabolite Disease Research Fields Source Classification Cancer	FXR Sirtuin TNF Receptor Interleukin Related
Geniposidic acid is an orally active FXR modulator and SIRT6 activator. Geniposidic acid binds to the Ser332 and His447 sites on the FXR ligand-binding domain, thereby driving nuclear translocation, coactivator recruitment, and transcription of downstream bile acid and cholesterol metabolism-related genes. Geniposidic acid improves metabolic dysfunction-related fatty liver disease by activating the SIRT6 signaling pathway. Geniposidic acid inhibits inflammation and modulates gut microbiota to alleviate colitis. Geniposidic acid can be used in research on drug-induced liver injury, inflammatory bowel disease, metabolic dysfunction-related fatty liver disease, and metabolic dysfunction-related steatohepatitis .

HY-B2176R

ATP (Standard) Adenosine 5'-triphosphate (Standard)	Structural Classification Alkaloids Human Gut Microbiota Metabolites Microorganisms other families Animals Other Alkaloids Plants Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite
ATP (Standard) is the analytical standard of ATP. This product is intended for research and analytical applications. ATP (Adenosine 5'-triphosphate) is a central component of energy storage and metabolism in vivo. ATP provides the metabolic energy to drive metabolic pumps and serves as a coenzyme in cells. ATP is an important endogenous signaling molecule in immunity and inflammation . In Vitro: ATP (5 mM; 1 hour) co-treatment with LPS (1 μg/mL) has a synergistic effect on the activation of the NLRP3 inflammasome in HGFs . ATP (2 mM; 0.5-24 hours) induces secretion of IL-1β, KC and MIP-2 from BMDMs in a caspase-1 activation-dependent manner . ATP promotes neutrophil chemotaxis in vitro . In Vivo: ATP (50 mg/kg; i.p.) protects mice against bacterial infection in vivo . ATP induces the secretion of IL-1β, KC and MIP-2 and neutrophils recruitment in vivo .

HY-P1680

Astin C Asterin	Natural Products Plants Compositae Erythrina latissima E. Mey. Source Classification	STING HSV
Astin C (Asterin) is a cyclopeptide that can be extracted from Aster tataricus. Astin C has anti-inflammatory and anti-cancer activities. Astin C can specifically inhibit the cGAS-STING signaling pathway, block the recruitment of IRF3 to the STING signalosome, and thus inhibit the innate inflammatory response. Astin C can be used in the research of autoimmune diseases and cancers .

HY-W020790

Sialyl-Lewis X 1 Publications Verification sLeX	Polysaccharides Classification of Application Fields Endogenous metabolite Inflammation/Immunology Disease Research Fields Saccharides Source Classification	Endogenous Metabolite
Sialyl-Lewis X (sLeX) is a sialylated fucosylated tetrasaccharide, an endogenous antigen. Sialyl-Lewis X is a high-affinity ligand for selectins (E-, P-, and L-selectin) . Sialyl-Lewis X binds to ELAM-1 and CD62 and has the ability?to inhibits CD62-mediated neutrophil recruitment to sites of inflammation .

HY-N3196

Neotuberostemonine	Alkaloids Classification of Application Fields Stemonaceae Plants Inflammation/Immunology Disease Research Fields Stemona tuberosa Lour. Indole Alkaloids Source Classification	Bacterial
Neotuberostemonine, one of the main antitussive alkaloids in the root of Stemona tuberosa Lour, attenuates bleomycin-induced pulmonary fibrosis by suppressing the recruitment and activation of macrophages .

HY-W585959

(E,E)-4,8,12-Trimethyl-1,3,7,11-tridecatetraene	Structural Classification Elettaria cardamomum (L.) Maton Terpenoids Sesquiterpenes Plants Source Classification Zingiberaceae	Insecticide
(E,E)-4,8,12-Trimethyl-1,3,7,11-tridecatetraene (TMTT), a sesquiterpene, is the major herbivore-induced plant volatile that help in defense directly by acting as repellants and indirectly by recruiting insects' natural enemies. (E,E)-4,8,12-Trimethyl-1,3,7,11-tridecatetraene attractes Asian corn borer (ACB, Ostrinia furnacalis) larvae. External supplementation with (E,E)-4,8,12-Trimethyl-1,3,7,11-tridecatetraene hampered the larvae's ability to locate pre-infested maize .

HY-W012078R

5-Methyl-2'-deoxycytidine (Standard) 1 Publications Verification 5-Methyldeoxycytidine (Standard)	Structural Classification Natural Products Endogenous metabolite Source Classification	Reference Standards DNA Methyltransferase Endogenous Metabolite
5-Methyl-2'-deoxycytidine (5mdC) is an endogenous substrate of DNA methyltransferases (such as mammalian 5-C-MTase) and binds to DNA dependent on the formation of DNA stem-loop structures. 5-Methyl-2'-deoxycytidine guides de novo DNA methylation by acting as a methylation mark and activates the methylation of adjacent CpG sites in single-stranded DNA through cis action. 5-Methyl-2'-deoxycytidine regulates DNA methylation patterns by recruiting methyltransferases to specific chromatin regions, affecting chromatin condensation and gene expression. Its distribution in plant cells is related to cell proliferation and differentiation stages. The methylation level of 5-Methyl-2'-deoxycytidine is low in proliferating cells and high in differentiated cells .

HY-N12919

(E)-3-Dodecenol	Natural Products Animals Source Classification	Others
(E)-3-Dodecenol is a termite trail pheromone that can be isolated from the whole body and thymus extracts of termite workers. (E)-3-Dodecenol induces orientational and recruitment behavior effects, but its induction effect is weaker than (Z)-Dodecenol or natural thymus extracts .

HY-N1749

2-Oxokolavenol	Structural Classification Terpenoids Aglaia lawii (Wight) C. J. Saldanha & Ramamorthy Diterpenoids Plants Meliaceae Source Classification	FXR
2-Oxokolavenol is a selective agonist targeting the farnesoid X receptor (FXR), with an EC₅₀ of ~3.7 μM. 2-Oxokolavenol exerts its activity against Acetaminophen (HY-66005)-induced hepatocyte damage in an FXR-dependent manner by binding to the FXR ligand-binding pocket, recruiting co-activators, and inducing FXR transcriptional activity. 2-Oxokolavenol can be naturally extracted from Aglaia spectabilis (a plant of the Aglaia genus in the Meliaceae family) and can be used in research related to liver diseases .

HY-W585885

(3E)-4,8-Dimethylnona-1,3,7-triene	Structural Classification Natural Products Poaceae Plants Melinis minutiflora P. Beauv. Source Classification	Insecticide
(3E)-4,8-Dimethylnona-1,3,7-triene, a sesquiterpene, is the major herbivore-induced plant volatile that help in defense directly by acting as repellants and indirectly by recruiting insects' natural enemies. (3E)-4,8-Dimethylnona-1,3,7-triene attractes Asian corn borer (ACB, Ostrinia furnacalis) larvae. External supplementation with (3E)-4,8-Dimethylnona-1,3,7-triene hampered the larvae's ability to locate pre-infested maize.

Cat. No.	Product Name	Chemical Structure

HY-W740027

5-Methyl-2'-deoxycytidine-d3

5-Methyl-2'-deoxycytidine-d₃ (5-Methyldeoxycytidine-d₃) is the deuterium labeled Methyl-2'-deoxycytidine (HY-W012078). 5-Methyl-2'-deoxycytidine (5mdC) is an endogenous substrate of DNA methyltransferases (such as mammalian 5-C-MTase) and binds to DNA dependent on the formation of DNA stem-loop structures. 5-Methyl-2'-deoxycytidine guides de novo DNA methylation by acting as a methylation mark and activates the methylation of adjacent CpG sites in single-stranded DNA through cis action. 5-Methyl-2'-deoxycytidine regulates DNA methylation patterns by recruiting methyltransferases to specific chromatin regions, affecting chromatin condensation and gene expression. Its distribution in plant cells is related to cell proliferation and differentiation stages. The methylation level of 5-Methyl-2'-deoxycytidine is low in proliferating cells and high in differentiated cells .

HY-126214S

JH-RE-06-d6
JH-RE-06-d6 is deuterium labele JH-RE-06. JH-RE-06, a potent REV1-REV7 interface inhibitor (IC₅₀=0.78 μM; K_i=0.42 μM), targets REV1 that interacts with the REV7 subunit of POLζ. JH-RE-06 disrupts mutagenic translesion synthesis (TLS) by preventing recruitment of mutagenic POLζ. JH-RE-06 improves chemotherapy .

HY-128423AS

Tylvalosin-d9
Tylvalosin-d₉ (Acetylisovaleryltylo?sin-d₉) is the deuterium labeled Tylvalosin (HY-128423A) . Tylvalosin is a third-generation macrolide, with anti-inflammatory property. Tylvalosin decreases the levels of IL-8, IL-6, IL-1β, PGE2, TNF-α and NO, and reduces the inflammatory cells recruitment and activation in mouse acute lung injury model .

HY-124356AS

Alcaftadine carboxylic acid-d3 sodium

Alcaftadine carboxylic acid-d₃ (sodium) is deuterium labeled Alcaftadine carboxylic acid. Alcaftadine carboxylic acid is a broad-spectrum antihistamine compound with high affinity for histamine H1 and H2 receptors and low affinity for H4 receptors. Alcaftadine carboxylic acid has also demonstrated effects on modulating immune cell recruitment and stabilizing mast cells. Alcaftadine carboxylic acid is more effective than placebo in preventing ocular itching associated with allergic conjunctivitis and is at least as effective as olopatadine 0.01% .

HY-139938S

(±)11(12)-EET methyl ester-d11

(±)11(12)-EET-d₁₁ methyl ester (11,12-EET methyl ester-d₁₁) is the deuterium labeled (±)11(12)-EET methyl ester (HY-139938). (±)11(12)-EET methyl ester (11,12-EET-methyl ester) is a methylated derivative of 11,12-epoxyeicosatrienoic acid (11,12-EET) (HY-130494). (±)11(12)-EET methyl ester cannot induce β-arrestin recruitment of the G protein-coupled receptor GPR132. (±)11(12)-EET methyl ester fails to enhance the expression of hematopoietic stem and progenitor cell (HSPC) markers. (±)11(12)-EET methyl ester can be used as a negative control molecule to study the structure-function relationship of 11,12-EET, facilitating the analysis of the role of the oxygenated fatty acid-GPR132 signaling axis in hematopoiesis .

HY-179551S

(±)11(12)-EET-d11 Methyl ester

(±)11(12)-EET-d₁₁ Methyl ester is the deuterium labeled (±)11(12)-EET methyl ester (HY-139938). (±)11(12)-EET methyl ester is a methylated derivative of 11,12-epoxyeicosatrienoic acid (11,12-EET) (HY-130494). (±)11(12)-EET methyl ester cannot induce β-arrestin recruitment of the G protein-coupled receptor GPR132. (±)11(12)-EET methyl ester fails to enhance the expression of hematopoietic stem and progenitor cell (HSPC) markers. (±)11(12)-EET methyl ester can be used as a negative control molecule to study the structure-function relationship of 11,12-EET, facilitating the analysis of the role of the oxygenated fatty acid-GPR132 signaling axis in hematopoiesis.

Cat. No.	Product Name		Classification

HY-176786

MCB-36		Alkynes
MCB-36 is a VHL-recruiting pan-KRAS PROTAC degrader without affecting KRAS transcription. MCB-36 exhibits minimal effects on HRAS and NRAS protein levels. MCB-36 binds to the GDP-loaded state of G12D, G12C, G12V, and wild-type KRAS with high affinities K_d ≈ 1 pM). MCB-36 decreases p-ERK levels, leading to cell apoptosis. MCB-36 effectively suppress KRAS ^G12C inhibitor-resistant cancer cells and remodel the tumor immune microenvironment. MCB-36 can be used for the study of colorectal cancer and lung cancer (Pink: Target protein ligand; Blue: E3 ligand (HY-112078); Black: Linker (HY-W091879)) .

HY-147858

PROTAC EGFR degrader 7		PROTAC Synthesis Alkynes
PROTAC EGFR degrader 7 (compound 13b) is a potent and selective CRBN-recruiting PROTAC EGFR ^L858R/T790M degrader, with a DC₅₀ of 13.2 nM. PROTAC EGFR degrader 7 inhibits NCI–H1975 cells proliferation, with an IC₅₀ of 46.82 nM. PROTAC EGFR degrader 7 significantly induces apoptosis and G2/M phase arrest in NCI–H1975 cell. PROTAC EGFR degrader 7 shows antitumor activity, and can be used for non-small cell lung cancer (NSCLC) research . PROTAC EGFR degrader 7 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-174995

JQ-1-Azidopropylamine		Azide
JQ-1-Azidopropylamine is an Target Protein Ligand-Linker Conjugate that incorporates a ligand for BRD4 (HY-78695) and a PROTAC linker (HY-151862), which recruits E3 ligases. JQ-1-Azidopropylamine can be used for synthesis of PROTAC JY-21 (HY-174975) .

HY-114402

ARD-69		PROTAC Synthesis
ARD-69 is a PROTAC degrader based on the E3 ubiquitin ligase VHL and targeting the androgen receptor, which can induce androgen receptor (AR) protein degradation in AR-positive prostate cancer cells. ARD-69 inhibits AR-regulated gene expression, binds to the AR ligand binding domain at one end and binds to VHL at the other end, prompting AR to be recruited to the E3 ubiquitin ligase complex, triggering proteasome degradation, thereby inhibiting AR signaling pathways and downstream gene expression (such as PSA, TMPRSS2). ARD-69 can be used to study of castration-resistant prostate cancer (mCRPC) . ARD-69 is composed of a target protein ligand (pink part) AR antagonist 14 (HY-172624), a PROTAC linker (black part) tert-Butyl 4-ethynyl-[1,4'-bipiperidine]-1'-carboxylate (HY-W442074), and a VHL-type E3 ubiquitinase ligand (blue part) VH 101, acid (HY-47070); among them, the VHL ligand and the linker can form a conjugate VH 101-amide-piperidine-Pip-alkyne (HY-172625).

HY-139339

Pomalidomide 4'-alkylC6-azide		Azide
Pomalidomide 4'-alkylC6-azide is the Pomalidomide (HY-123324)-based cereblon (CRBN) ligand used in the recruitment of CRBN protein. Pomalidomide 4'-alkylC6-azide can be connected to the ligand for protein by a linker to form PROTAC .

HY-126457

Thalidomide-propargyl		Alkynes
Thalidomide-propargyl is the Thalidomide-based Cereblon ligand used in the recruitment of CRBN protein. Thalidomide-propargyl can be connected to the ligand for protein by a linker to form the IMiD containing PROTACs . Thalidomide-propargyl is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-175247

DDO-4033		Alkynes
DDO-4033 is a SPOP inhibitor (IC₅₀ = 16.9 μM, K_d = 15.1 μM). DDO-4033 impairs the malignant migration, invasion, and proliferation of clear cell renal cell carcinoma (ccRCC) cell lines. DDO-4033 disrupts SPOP recruitment to its substrate LATS1, inhibits its polyubiquitination and subsequent degradation, and upregulates LATS1 expression. DDO-4033 has promising antitumor activity and is promising for renal cell carcinoma research .

HY-101460

Tz-Thalidomide		Tetrazine
Tz-Thalidomide is a tetrazine-tagged Thalidomide (HY-14658), an E3 ligase ligand. Tz-Thalidomide self-assembles with TCO-labeled target protein inhibitors, forming a CLIP-TAC (targeted protein degradation chimera) via click chemistry. This chimera recruits the E3 ubiquitin ligase CRBN to the target protein, thereby inducing ubiquitination and subsequent degradation of the target protein. When used in combination with JQ1-TCO (HY-148864), Tz-Thalidomide induces concentration-dependent degradation of BRD4 in cells. When combined with ERK-targeting protein inhibitors, Tz-Thalidomide induces degradation of ERK1/2 in cells. Tz-Thalidomide can be used in cancer-related research .

HY-W458035

Desamino lenalidomide-alkynes		Alkynes
Desamino lenalidomide-alkynes is an E3 ubiquitin ligase cereblon (CRBN) ligand used to recruit the cereblon protein. Desamino lenalidomide-alkynes can be linked to a target protein ligand via a linker to form a PROTAC.

HY-W1130361

(S,R,S)-AHPC-PEG5-Azide		Azide
(S,R,S)-AHPC-PEG5-Azide is a VHL ligand based on (S,R,S)-AHPC that recruits von Hippel-Lindau (VHL) protein. (S,R,S)-AHPC-PEG5-Azide can be linked to a target protein ligand via a linker to form a PROTACs.

HY-162507

2'-RIBOTAC-U recruiter-linker		Alkynes
2'-RIBOTAC-U recruiter-linker (Compound 9) consists of RNase L recruiter and linker. 2'-RIBOTAC-U recruiter-linker is reacted separately with 2’-azido-uridine or 5’-azidomethyl-uridine via copper-catalyzed click chemistry, resulting in the formation of 2’-RIBOTAC-U and 5’-RIBOTAC-U, respectively. 2’-RIBOTAC-U has anti-SARS-CoV-2 activity .

HY-168458

RNA recruiter-linker 1		Alkynes
RNA recruiter-linker 1 is the RNA ligand-linker part of RNAse L RIBOTAC (HY-168455), an RNA-degrading chimera which binds to a four-way RNA helix called SL5 in the 5’ UTR of the SARS-CoV-2 RNA genome and inhibits the virus replication in lung epithelial carcinoma cells. RNA recruiter-linker 1 can be utilized in the synthesis of RIBOTAC .

HY-161134

Lenalidomide 4'-PEG2-azide		Azide
Lenalidomide 4'-PEG2-azide is the Lenalidomide-based Cereblon ligand used in the recruitment of CRBN protein. Lenalidomide 4'-PEG2-azide can be connected to the ligand for protein by a linker to form PROTAC .

HY-157182

DNP-PEG2-NHCO-C2-DBCO		DBCO
DNP-PEG2-NHCO-C2-DBCO is a clickable hapten that bears a dinitrophenyl (DNP) moiety as the antibody‐recruiting motif at one end, a polyethylene glycol chain as a spacer and a dibenzocyclooctene at the other end for the SPAAC chemistry .

HY-139332

Pomalidomide 4'-PEG6-azide		Azide
Pomalidomide 4'-PEG6-azide (compound 33e) is the E3 ligase ligand-linker conjugate used in the recruitment of CRBN protein. Pomalidomide 4'-alkylC3-acid can be used to synthesize PROTACs .

HY-139333

Pomalidomide 4'-PEG5-azide		Azide
Pomalidomide 4'-PEG5-azide is the Pomalidomide (HY-123324)-based cereblon (CRBN) ligand used in the recruitment of CRBN protein. Pomalidomide 4'-PEG5-azide can be connected to the ligand for protein by a linker to form PROTAC .

HY-157514

Thalidomide 4'-ether-PEG1-azide		Azide
Thalidomide 4'-ether-PEG1-azide is the Thalidomide (HY-14658)-based cereblon ligand used in the recruitment of CRBN protein. Thalidomide 4'-ether-PEG1-azide can be connected to the ligand for protein by a linker to form PROTACs .

HY-181530

IAP ligand 6		PROTAC Synthesis
IAP ligand 6 (A250) is an IAP ligand with a K_a value of 0.1 μM for the human XIAP BIR3 domain. IAP ligand 6 binds to the XIAP BIR3 domain and serves as an alkynylpyridine scaffold for the preparation of TEAD degraders that recruit IAP. IAP ligand 6 is applicable to research related to mesothelioma .

Cat. No.	Product Name		Classification

HY-108610A

Edelfosine 1 Publications Verification ET-18-OCH3		Phospholipids
Edelfosine (ET-18-OCH3) is an orally active lipid raft modulator and apoptosis inducer that alters membrane fluidity and preferentially inserts into tumor cell membranes. Edelfosine recruits death receptor ligands (FasL/CD95L, TRAIL) and Bid to lipid rafts to form death-inducing signaling complexes, thereby initiating mitochondria-dependent apoptosis and inducing cytochrome c release. Edelfosine also exerts anti-inflammatory effects, promotes L-Selectin shedding, and causes no gastrointestinal or organ toxicity. In addition, Edelfosine inhibits nucleic acid and protein synthesis in Leishmania donovani and exhibits antiproliferative activity. Edelfosine can be used in research on multiple myeloma, inflammatory bowel diseases (such as ulcerative colitis and Crohn's disease), and visceral leishmaniasis .

HY-148457

Avacincaptad pegol Izervay		Aptamers
Avacincaptad pegol (Izervay) is a selective inhibitor targeting complement component C5, and is a pegylated ribonucleic acid aptamer. Avacincaptad pegol inhibits the cleavage of C5 into pro-inflammatory C5a and C5b, which forms the membrane attack complex (C5b-9), thereby reducing inflammatory cell recruitment and retinal cell damage. Avacincaptad pegol can slow the growth of geographic atrophy (GA) lesions and reduce the risk of persistent vision loss. Avacincaptad pegol can be used in research of geographic atrophy associated with age-related macular degeneration (AMD) and has been approved by the FDA .

HY-145726

ISIS 104838		Antisense Oligonucleotides
ISIS 104838 is an antisense oligonucleotide targeting TNF-α. ISIS 104838 specifically binds to human TNF-α mRNA via Watson-Crick base pairing to form a DNA:RNA hybrid duplex, thereby recruiting the ubiquitously expressed intracellular enzyme RNase H to degrade the target mRNA and inhibit TNF-α protein synthesis at the transcriptional level. ISIS 104838 induces moderate, self-limiting thrombocytopenia in cynomolgus monkeys. ISIS 104838 can be used for the study of inflammatory diseases .

HY-148511

Vidutolimod CMP-001		CpG ODNs
Vidutolimod (CMP-001) is a virus-like particle containing a TLR9 activator . Vidutolimod induces human peripheral blood mononuclear cells to secrete IFNα, and upregulates the gene expression of CXCL10, PDL1, IDO and CD80. Vidutolimod activates TLR9, which in turn triggers plasmacytoid dendritic cell activation, production of IFNγ and TNFα, induction of CXCL10, and recruitment of antitumor T cells. Vidutolimod causes influenza-like symptoms, hypotension and tumor regression, and its activity depends on the presence of anti-Qβ antibodies. Vidutolimod modulates monocyte function, promotes CD4 T cell proliferation, and activates multiple immune cell types in an environment with anti-Qβ antibodies. Vidutolimod prolongs the survival of tumor-bearing mice. Vidutolimod is used in research related to advanced melanoma, head and neck squamous cell carcinoma, and advanced non-small cell lung cancer .

HY-145726A

ISIS 104838 sodium		Antisense Oligonucleotides
ISIS 104838 sodium is an antisense oligonucleotide targeting TNF-α. ISIS 104838 sodium specifically binds to human TNF-α mRNA via Watson-Crick base pairing to form a DNA:RNA hybrid duplex, thereby recruiting the ubiquitously expressed intracellular enzyme RNase H to degrade the target mRNA and inhibit TNF-α protein synthesis at the transcriptional level. ISIS 104838 sodium induces moderate, self-limiting thrombocytopenia in cynomolgus monkeys. ISIS 104838 sodium can be used for the study of inflammatory diseases .

HY-145976

m7GpppGpG		Cap Analogs
m7GpppGpG, an oligonucleotide, is an M ⁷GpppNpG trinucleotide cap analogue. m7GpppGpG prevents premature degradation by 5′-exonucleases and recruits proteins required for pre-mRNA splicing, mRNA transport and initiation of protein biosynthesis .

HY-174770

Human CCL13 mRNA		mRNA Chemokine & Receptors
Human CCL13 mRNA encodes the human C-C motif chemokine ligand 13 (CCL13) protein, a cytokine that displays chemotactic activity for monocytes, lymphocytes, basophils and eosinophils, but not neutrophils. CCL13 also plays a role in accumulation of leukocytes during inflammation and may be involved in the recruitment of monocytes into the arterial wall during artherosclerosis.

HY-174748

Human CCR1 mRNA		mRNA Chemokine & Receptors
Human CCR1 mRNA encodes the human C-C motif chemokine receptor 1 (CCR1) protein, a member of the beta chemokine receptor family. Chemokines and their receptors are critical for the recruitment of effector immune cells to the site of inflammation.

HY-174739

Human CCRL2 mRNA		mRNA Chemokine & Receptors
Human CCRL2 mRNA encodes the human C-C motif chemokine receptor like 2 (CCRL2) protein, a chemokine receptor like protein. Chemokines and their receptors mediated signal transduction are critical for the recruitment of effector immune cells to the site of inflammation.

HY-174602

Human IL5 mRNA		mRNA Interleukin & Receptors
Human IL5 mRNA encodes the human interleukin 5 (IL5) protein, a cytokine that acts as a growth and differentiation factor for both B cells and eosinophils. IL5 plays a major role in the regulation of eosinophil formation, maturation, recruitment and survival. The increased production of this cytokine may be related to pathogenesis of eosinophil-dependent inflammatory diseases.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

recruiting

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

Natural
Products